GSK Relvar Ellipta 92/22 inhalation powder

Relvar Ellipta is a prescription-only pharmaceutical product used for the regular treatment of asthma and chronic obstructive pulmonary disease (COPD). The medicine is a combination of two active ingredients, fluticasone furoate (an inhaled corticosteroid) and vilanterol (a long-acting beta2-agonist), designed for once-daily administration.

Originally developed through a collaborative partnership between the British multinational pharmaceutical giant GlaxoSmithKline (GSK) and the American biopharmaceutical company Innoviva (formerly Theravance), the brand carries significant heritage in respiratory medicine. The Ellipta device itself is a signature dry powder inhaler developed by GSK to improve ease of use and dosage consistency.

Manufacturing primarily takes place at GSK’s specialized facility in Ware, United Kingdom, which serves as a global hub for respiratory products. Ownership remains with GSK, one of the world's largest pharmaceutical companies, headquartered in London. The product is distributed locally in various regions by GSK's national subsidiaries, such as GSK España for the Spanish market, ensuring compliance with local healthcare regulations.